代謝を超えて:性機能障害と減量薬
Jenyfer M Fuentes-Mendoza1, Marcio J Concepción-Zavaleta1, Jeny J Mendoza-Godoy2
1Grupo de Investigación en Neurociencias, Metabolismo, Efectividad Clínica y Sanitaria, Universidad Científica del Sur, Lima 15067, Peru.
Sexual medicine reviews
|December 22, 2025
まとめ
新しい減量薬は性機能に様々な影響を示し、男性には一部効果があるものの、女性のデータは限られています。これらの性健康への影響を理解するには、さらなる研究が必要です。
科学分野:
- 内分泌学
- 薬理学
- 性医学
背景:
- 肥満は、ホルモン、血管、代謝、心理社会的要因を介して性機能障害(SD)と関連しています。
- 減量は一般的に性的な健康を改善しますが、新しい減量薬の影響はよく理解されていません。
主な方法:
- PubMed、Scopus、Embaseの文献の包括的なナラティブレビュー。
- 肥満、SD、薬物療法に関連する用語を検索しました。
- 検証済みの楽器(FSFI、IIEF)または臨床報告を使用して性的な転帰を報告した研究を含めました。
結論:
- 減量薬は様々な経路で性的な健康に影響を与えますが、エビデンスは一貫していません。
- 性別特異的なデータや併存疾患に関する研究は乏しいです。
- 将来の試験では、性別で層別化された主要な転帰として、検証済みの性機能測定値が必要です。
関連する概念動画
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
218
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
218
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
153
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
153
Drug Dosing: Obese Patients
195
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
195
Disorders of the Male Reproductive System
3.9K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
3.9K
Antidepressant Drugs: MAOIs and Other Agents
765
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
765
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
234
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234


